Additionally, the CRG signature also exerted its influence on the patients’ sensitivity to methotrexate, especially suitable for low-risk BC patients with wild-type FGFR3; however, its applicability for BC patients in clinic was rare, which needed more verification. Here, FGFR3 is linked to breast cancer.